SCHEMBL985219

SCHEMBL985219

Cn1ccc2cc(C3(Cc4ccccc4)CCN(Cc4ccccc4)C3)ccc21

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.64
SLC6A4 P31645 3/20 0.64
SLC6A3 Q01959 3/20 0.64
CYP2D6 P10635 2/20 0.64
KCNH2 Q12809 1/20 0.64
KDM4E B2RXH2 1/20 0.46
KMT2A Q03164 1/20 0.46
NR3C1 P04150 2/20 0.43
FAAH O00519 1/20 0.43
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
CCR3 P51677 1/20 0.38
CYP3A4 P08684 2/20 0.38
CYP1A2 P05177 1/20 0.38
CHRNA7 P36544 1/20 0.38
POLB P06746 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982085 0.89 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL12923048 0.84 CYP2D6 (0.46) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL981974 0.84 CYP2D6 (0.46) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL985221 0.82 CYP2D6 (0.45) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL983147 0.82 CYP2D6 (0.44) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL982934 0.79 CYP2D6 (0.42) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL12948987 0.78 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL981431 0.78 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
Indole SCHEMBL2794626 0.77 CYP2D6 (0.43) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2
SCHEMBL984260 0.76 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3CYP2D6KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 SLC6A2 6/4885SLC6A4 8/4885SLC6A3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.